VPS35/Retromer Pathway in Parkinson's Disease

VPS35/Retromer Pathway in Parkinson's Disease

Overview

The VPS35 (Vacuolar Protein Sorting 35) gene encodes a core component of the retromer complex, a conserved endosomal-lysosomal sorting machinery critical for transmembrane protein recycling. The retromer plays a essential role in neuronal cells by directing cargo proteins from endosomes back to the trans-Golgi network or the plasma membrane. Mutations in VPS35, particularly the pathogenic p.D620N variant, have been definitively linked to autosomal dominant Parkinson's disease (PD), establishing the retromer pathway as a key molecular mechanism in neurodegeneration. [@retromer2021]

Molecular Biology of the Retromer Complex

Core Structure and Function

The retromer is a heteropentameric complex that associates with the sorting nexin (SNX) family proteins to form a versatile cargo recognition and transport machinery. The core retromer consists of: [@endosomallysosomal2020]

• VPS35 (Vacuolar Protein Sorting 35): The 796-amino acid scaffold protein that forms the central core of the complex
• VPS26 (VPS26A/VPS26B): A subunit that recognizes cargo proteins through specific recognition motifs
• VPS29: A subunit that coordinates the assembly and function of the complex

The retromer operates in concert with the BIN/MACPF domain-containing proteins (such as VPS5/VPS4 in yeast) and various SNX proteins, including SNX1, SNX2, SNX5, and SNX6, which form a tubulation module responsible for membrane remodeling. [@vps2018a]

Cargo Recognition and Sorting

...

VPS35/Retromer Pathway in Parkinson's Disease

Overview

The VPS35 (Vacuolar Protein Sorting 35) gene encodes a core component of the retromer complex, a conserved endosomal-lysosomal sorting machinery critical for transmembrane protein recycling. The retromer plays a essential role in neuronal cells by directing cargo proteins from endosomes back to the trans-Golgi network or the plasma membrane. Mutations in VPS35, particularly the pathogenic p.D620N variant, have been definitively linked to autosomal dominant Parkinson's disease (PD), establishing the retromer pathway as a key molecular mechanism in neurodegeneration. [@retromer2021]

Molecular Biology of the Retromer Complex

Core Structure and Function

The retromer is a heteropentameric complex that associates with the sorting nexin (SNX) family proteins to form a versatile cargo recognition and transport machinery. The core retromer consists of: [@endosomallysosomal2020]

• VPS35 (Vacuolar Protein Sorting 35): The 796-amino acid scaffold protein that forms the central core of the complex
• VPS26 (VPS26A/VPS26B): A subunit that recognizes cargo proteins through specific recognition motifs
• VPS29: A subunit that coordinates the assembly and function of the complex

The retromer operates in concert with the BIN/MACPF domain-containing proteins (such as VPS5/VPS4 in yeast) and various SNX proteins, including SNX1, SNX2, SNX5, and SNX6, which form a tubulation module responsible for membrane remodeling. [@vps2018a]

Cargo Recognition and Sorting

The retromer recognizes cargo proteins through multiple mechanisms: [@microglial2022]

Motif-based recognition: The VPS26 subunit binds to specific peptide motifs in the cytoplasmic tails of transmembrane proteins

Phosphoinositide binding: SNX proteins contain PX domains that bind to phosphatidylinositol-3-phosphate (PI3P) on endosomal membranes

Cargo adaptors: Additional proteins such as SNX3, SNX27, and WASH complex members extend cargo specificity

Key cargo proteins relevant to Parkinson's disease include: [@retromer2021a]

• Cation-independent mannose-6-phosphate receptor (CI-M6PR): Critical for lysosomal enzyme delivery
• Amyloid precursor protein (APP): Central to Alzheimer's disease pathogenesis
• Dopamine transporter (DAT): Essential for dopamine reuptake
• TREM2: Microglial receptor involved in amyloid clearance
• LRRK2: Leucine-rich repeat kinase 2, another PD-associated protein

VPS35 Mutations in Parkinson's Disease

The D620N Mutation

The VPS35 p.D620N (c.1858G>A) missense mutation was identified in 2013 as a cause of autosomal dominant Parkinson's disease. This mutation represents one of the most penetrant genetic causes of PD identified to date, with carriers showing typical late-onset parkinsonian symptoms. [@wash2015]

Key characteristics of VPS35-D620N: [@snx2020]

• Inheritance: Autosomal dominant
• Penetrance: High (near complete by age 80)
• Age of onset: Typically 50-65 years
• Clinical phenotype: Indistinguishable from idiopathic PD
• Response to levodopa: Generally good

Mechanism of Pathogenesis

The D620N mutation impairs retromer function through several mechanisms: [@geneenvironment2021]

Reduced cargo sorting efficiency: The mutation decreases the ability of the retromer to properly sort specific cargo proteins

Altered endosomal morphology: Dysregulated retromer function leads to abnormal endosomal accumulation and trafficking defects

Impaired lysosomal function: Defective retromer trafficking compromises lysosomal enzyme delivery and protein degradation

Synaptic dysfunction: Altered trafficking of synaptic proteins affects neurotransmitter release and reuptake

Retromer Dysfunction in Neurodegeneration

Endosomal-Lysosomal Pathway Impairment

The retromer plays a critical role in maintaining endosomal-lysosomal function. Dysfunction leads to: [@retromer2022]

• Endosomal cargo accumulation: Accumulation of undigested materials within swollen endosomes
• Lysosomal enzyme misrouting: Impaired delivery of hydrolytic enzymes to lysosomes
• Autophagic dysfunction: Disrupted protein clearance through the autophagy-lysosome pathway
• Lipid metabolism defects: Altered sphingolipid and cholesterol trafficking

Protein Aggregation

Retromer impairment contributes to pathological protein aggregation: [@clinical2018]

• Alpha-synuclein: Altered processing and reduced lysosomal clearance promote aggregation
• Amyloid precursor protein: Dysregulated APP trafficking affects amyloid-beta production
• Tau protein: Impaired lysosomal function contributes to tau pathology

Mitochondrial Dysfunction

The retromer affects mitochondrial quality control through:

• Trafficking of mitochondrial proteins: Altered delivery of proteins involved in mitochondrial dynamics
• Mitophagy receptors: Impaired clearance of damaged mitochondria
• Energy metabolism: Disrupted neuronal energy supply

Therapeutic Implications

Small Molecule Retromer Stabilizers

Pharmacological approaches to enhance retromer function include:

Retromer agonists: Small molecules that stabilize the retromer complex and enhance its function

Protein-protein interaction inhibitors: Compounds that enhance retromer-cargo interactions

Phosphoinositide modulators: Agents that improve endosomal membrane composition

Gene Therapy Approaches

• VPS35 wild-type delivery: Viral vector-mediated gene therapy to restore normal retromer function
• SNX3 overexpression: Enhancing cargo recognition capacity
• RNAi against mutant VPS35: allele-specific silencing

Target Validation Strategies

Therapeutic development focuses on:

• Biomarkers of retromer function: Measuring cargo sorting efficiency
• Endosomal morphology markers: Imaging-based assessment of cellular pathology
• Clinical outcome measures: PD progression markers in clinical trials

Biomarkers and Diagnostic Applications

Genetic Testing

• Presymptomatic testing: Available for individuals with family history
• Carrier identification: Enables genetic counseling
• Phenotype prediction: Variable expressivity suggests modifier genes

Biomarkers of Retromer Dysfunction

• Cerebrospinal fluid markers: Altered levels of lysosomal enzymes
• Imaging markers: PET-based assessment of endosomal function
• Blood biomarkers: Peripheral markers of neuronal dysfunction

Animal Models

Genetic Models

• VPS35-D620N knock-in mice: Recapitulate key features of retromer dysfunction
• Conditional knockout models: Tissue-specific deletion to study neuronal effects
• Transgenic overexpression models: Wild-type and mutant VPS35 expression

Phenotypic Characteristics

• Motor deficits: Age-dependent parkinsonian features
• Cognitive impairment: Learning and memory deficits
• Neuropathology: Alpha-synuclein pathology, neuroinflammation
• Biochemical changes: Impaired autophagy, altered neurotransmitter systems

Research Directions

Current Clinical Trials

Several therapeutic approaches targeting the retromer pathway are in development:

• Phase I/II trials of retromer-stabilizing compounds
• Gene therapy approaches for VPS35-related PD
• Combination therapies targeting multiple aspects of retromer dysfunction

Emerging Research Areas

Modifier genes: Understanding genetic modifiers that influence VPS35 penetrance

Cell-type specificity: Identifying why dopaminergic neurons are particularly vulnerable

Developmental vs. degenerative mechanisms: Role of retromer in neuronal development vs. aging

Cross-disease mechanisms: Shared pathways between PD, AD, and other neurodegenerative diseases

Cross-Linking to Related Pathways

The VPS35/retromer pathway intersects with multiple neurodegenerative disease mechanisms:

• [Lysosomal Dysfunction](/mechanisms/lysosomal-dysfunction): Retromer is essential for lysosomal enzyme trafficking
• [Protein Aggregation](/mechanisms/protein-aggregation): Impaired clearance promotes protein aggregate formation
• [Mitochondrial Dysfunction](/mechanisms/mitochondrial-dysfunction-pathway): Cross-talk between retromer and mitochondrial quality control
• [Autophagy-Lysosomal Pathway](/mechanisms/autophagy-lysosomal-pathway): Retromer coordinates with autophagy for protein clearance
• [Neuroinflammation](/mechanisms/neuroinflammation-pathway): Microglial retromer dysfunction affects inflammatory responses

Related Pages

• [LRRK2 Gene](/genes/lrrk2): Another PD-associated gene interacting with retromer function
• [GBA Gene](/genes/gba): Lysosomal gene with overlapping pathology
• [[Parkinson's Disease](/diseases/parkinsons-disease): Primary disease context](/diseases/parkinsons-disease)
• [Dystonia](/diseases/dystonia): Clinical manifestation in some VPS35 carriers
• [[Alpha-Synuclein Aggregation Pathway](/mechanisms/alpha-synuclein-aggregation-pathway): Downstream pathological consequence](/proteins/alpha-synuclein)

See Also

• [Lysosomal Dysfunction](/mechanisms/lysosomal-dysfunction)
• [Protein Aggregation](/mechanisms/protein-aggregation)
• [Mitochondrial Dysfunction](/mechanisms/mitochondrial-dysfunction-pathway)
• [Autophagy-Lysosomal Pathway](/mechanisms/autophagy-lysosomal-pathway)
• [Neuroinflammation](/mechanisms/neuroinflammation-pathway)
• [LRRK2 Gene](/genes/lrrk2)
• [GBA Gene](/genes/gba)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Dystonia](/diseases/dystonia)
• [Alpha-Synuclein Aggregation Pathway](/mechanisms/alpha-synuclein-aggregation-pathway)

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
• [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

Detailed Molecular Mechanisms

Retromer Assembly and Membrane Association

The retromer complex assembles through a stepwise process that ensures proper localization and function:

The membrane associa-### Endosomal Sorting Complexes

Beyond the core retromer, several associated complexes participate in endosomal sorting:

WASH Complex

The Wiskott-Aldrich syndrome protein and SCAR homologue (WASH) complex:

• Function: Induces actin polymerization on endosomal membranes
• Components: WASH, FAM21, strumpellin, Vps35L, CCDC53
• Regulation: Controlled by Arp2/3 and Rac1 GTPase signaling

SNX-BAR Proteins

Sorting nexin proteins with Bin/Amphiphysin/Rvs (BAR) domains:

• Membrane deformation: Induce tubulation and vesicle formation
• SNX1/SNX2: Form heterodimers that tubulate membranes
• SNX5/SNX6: Partner with SNX1/2 for complete tubulation

Rab GTPase Coordination

The retromer functions in coordination with Rab GTPases:

• Rab5: Regulates early endosome identity and PI3P production
• Rab7: Controls late endosomal trafficking and lysosomal fusion
• Rab11: Mediates recycling to the plasma membrane
• Rab32: Regulates retromer recruitment to specific compartments

VPS35 and Synaptic Function

Presynaptic Vesicle Recycling

The retromer critically participates in synaptic vesicle recycling:

Postsynaptic Receptor Trafficking

Post-synaptic effects inclu

• AMPA receptor recycling: Regulates synaptic plasticity
• NMDA receptor- Dopamine ### Synaptic Vesicle Dynamics

The retromer affects multiple aspects of synaptic function:

• Vesicle biogenesis: Formation of synaptic-like microvesicles
• Vesicle pool maintenance: Preserves vesicle reserves
• Release probability: Modulates neurotransmitter release efficiency
• Short-term plasticity: Affects facilitation and depression

Impact on Dopaminergic Neurons

Specific Vulnerability Mechanisms

Dopaminergic neurons exhibit particular sensitivity to retromer dysfunction:

Dopamine Homeostasis

The retromer

• Tyrosine hydroxylase trafficking: Rate-limiting enzym- Dopamine transporter (DAT) recycling: Critical for reuptake
• **Vesicular monoamine tra### Neurodegeneration Cascade

Retromer dysfunction triggers a cascade in dopaminerg

Dru

High-Throughput Screeni- Cell-b#- Crystal structures of retromer components

• Cryo-EM structures of retromer complexes
• Virtu- Rational optimization of hits

Clinical Development Stages

| Stage | Focus ||-------|---| Preclinical | Target validation, lead opt| Phase I | S| Phase I|

Combination Therapies

Rational combinations - Retromer stabilizer + alpha-synuclein inhibitor: Targ- Retromer enhancer + autophagy inducer: Enhancing protein clearance

• Retromer therapy + antioxidant: Addressing oxidative stress
• Gene therapy + small molecule: Combining approaches

Pharmacological Modulation

Retromer-Targeting Compounds

Several classes of compounds have been identified:

Pharmacokinetics Considerations

• Blood-brain barrier penetration: Essential for CNS efficacy
• Dosing regimen: Balanced half-life and exposure
• Metabolic stability: Liver enzyme considerations
• Drug-drug interactions:

Genetic Modifiers and Penetrance

Modifier Genes

The variable penetrance of

Environmental Factors

Environmental influences on VPS35 penetrance:

• Pesti- Head trauma**: May accelerate neurodegeneration
• Smoking: Complex relationship with PD
• Caffeine co- Exercise**: May enhance cellular resilience

F

Key Knowledge Gaps

Emerging Technologies

• Single-cell sequencing:- Proteomics: Global changes in protein e- Metabolom- CRISPR screening: Genetic modifiers and therapeutic t- iPSC models**: Patient-derived neurons for study

Precisio

• Genotype-guided therapy: Variant-specific treatmen-- Combination therapy: Personalized multi-target approaches
• Preventive intervention: Pre-symptomatic treatment

Compr### The D

The D620N mutation represents one of the most functionally significant amino acid substitutions identified in Parkinson's disease genetiThe pathogenic mechanism of D620N extends beyond simple complex destabilization. Studies have demonstrated that the mutation specifically affects the retromer's ability to sort a subset of cargo proteins wh### Endosom
The retromer operates at the intersection of multiple membrane trafficking pathways, and its dysfunction has profound consequences for cellular homeostasis. Understanding the endosomal dynamics affected by VPS35 mutations requires consideration of the complex choreography of membrane trafficking events that maintain cellular function.

Early endosomes represent the primary site of retromer activity, serving as sorting stations where incoming cargo from the plasma membrane and biosynthetic pathways is distributed to various cellular destinations. The retromer functions to select cargo destined for recycling to the plasma membrane or retrieval to the trans-Golgi network, while allowing other cargo to proceed to lysosomes for degradation. VPS35 mutations disrupt this sorting function, leading to the inappropriate delivery of cargo proteins to lysosomes or their retention in endosomal compartments.

The formation of tubular protrusions from endosomal membranes represents a key step in the retromer-mediated sorting process. These tubules serve as carriers for the transport of recycled cargo to their destination compartments. The SNX-BAR proteins, which associate with the core retromer complex, drive tubule formation through their ability to bend membranes. In cells with VPS35 mutations, the efficiency of tubule formation is reduced, resulting in impaired cargo export from endosomes and the accumulation of cargo within swollen endosomal compartments.

Lysosomal trafficking represents another critical pathway affected by retromer dysfunction. While the retromer primarily functions in recycling pathways, its proper function is required for the maintenance of lysosomal homeostasis. This occurs through the retromer's role in trafficking the cation-independent mannose-6-phosphate receptor, which is essential for the delivery of newly synthesized lysosomal enzymes to lysosomes. When retromer function is impaired, lysosomal enzyme delivery is compromised, leading to reduced lysosomal hydrolytic capacity and the accumulation of undegraded materials within lysosomal compartments.

Autophagy-Lysosome Pathway Integration

The retromer and autophagy pathways intersect at multiple levels, with implications for protein homeostasis and cellular stress responses. Autophagy, the process by which cells degrade and recycle cytoplasmic components, relies on lysosomal function, which as discussed above is dependent on proper retromer activity.

Macroautophagy involves the formation of double-membrane vesicles called autophagosomes that engulf cytoplasmic components and then fuse with lysosomes for degradation. The efficiency of autophagosome-lysosome fusion depends on proper lysosomal function, which requires the delivery of lysosomal enzymes via the mannose-6-phosphate receptor pathway. VPS35 mutations impair this delivery, reducing lysosomal enzyme activity and compromising autophagic flux.

Chaperone-mediated autophagy represents another pathway affected by retromer dysfunction. This selective autophagy pathway relies on the recognition of specific cytosolic proteins by lysosomal receptors. The trafficking of these receptors, including LAMP-2A, is dependent on proper endosomal-lysosomal sorting, which is compromised in cells with VPS35 mutations.

The accumulation of autophagic substrates in neurons with VPS35 mutations provides a mechanism for the observed increase in protein aggregation. Under normal conditions, the autophagy-lysosome pathway clears damaged proteins and organelles. When this pathway is compromised, potentially aggregation-prone proteins accumulate, increasing the likelihood of pathological aggregate formation.

Mitochondrial Quality Control

Mitochondrial dysfunction represents a central feature of Parkinson's disease pathogenesis, and the retromer plays an important role in mitochondrial quality control. The relationship between retromer function and mitochondrial health involves multiple mechanisms that together ensure proper mitochondrial maintenance.

Mitophagy, the selective autophagy of mitochondria, represents a critical pathway for removing damaged mitochondria. This process is initiated by the recognition of damaged mitochondria by specific receptors that trigger their engulfment by autophagosomes. The function of these receptors, including PINK1 and parkin, depends on proper trafficking through the endosomal-lysosomal system, which is compromised in cells with retromer dysfunction.

Beyond mitophagy, the retromer affects mitochondrial function through the trafficking of mitochondrial proteins. Many proteins essential for mitochondrial dynamics, including fission and fusion proteins, are synthesized in the cytoplasm and must be imported into mitochondria. The proper trafficking and delivery of these proteins depends on endosomal sorting pathways that involve the retromer.

The electron transport chain complexes, essential for ATP production, require proper assembly and maintenance. Several components of these complexes are synthesized in the cytoplasm and require trafficking for proper mitochondrial localization. Retromer dysfunction impairs these trafficking pathways, potentially leading to impaired mitochondrial bioenergetics.

Neuroinflammatory Consequences

The retromer's role in glial cells, particularly microglia, has emerged as an important aspect of its function in the brain. Microglia are the resident immune cells of the central nervous system and play critical roles in neuronal support, debris clearance, and immune surveillance.

TREM2, discussed in detail elsewhere in this knowledge base, represents a key microglial receptor whose trafficking depends on retromer function. The proper surface expression and signaling of TREM2 is essential for microglial phagocytosis and inflammatory responses. VPS35 mutations impair TREM2 trafficking, reducing microglial ability to clear debris and respond appropriately to pathological stimuli.

The complement system, an important component of the innate immune response, also depends on proper retromer function for optimal activity. Several complement proteins require trafficking through the secretory pathway, and impaired retromer function reduces their proper localization and function.

Neuroinflammation in Parkinson's disease is characterized by increased levels of pro-inflammatory cytokines in the brain and cerebrospinal fluid. The retromer's role in regulating glial cell function suggests that its dysfunction may contribute to the chronic neuroinflammation observed in PD patients.

Clinical Translation and Therapeutic Outlook

The identification of VPS35 mutations as a cause of Parkinson's disease has opened new avenues for therapeutic development. The retromer represents an attractive therapeutic target because its enhancement may benefit multiple aspects of neuronal function.

Retromer-stabilizing compounds represent the most direct therapeutic approach. These small molecules are designed to enhance the assembly and function of the retromer complex, potentially compensating for the deficits caused by pathogenic mutations. Several such compounds have been developed and are in various stages of preclinical and clinical development.

Gene therapy approaches offer the potential for more direct correction of retromer dysfunction. Viral vector-mediated delivery of wild-type VPS35 could restore proper retromer function in affected neurons. However, challenges remain in achieving adequate expression levels and ensuring proper cellular targeting.

Combination therapies that target multiple aspects of retromer dysfunction may prove most effective. For example, combining retromer enhancement with therapies targeting alpha-synuclein aggregation or mitochondrial dysfunction could address multiple aspects of the pathogenic cascade.

Biomarker development remains an important priority for clinical trials targeting VPS35-related PD. Biomarkers that can track retromer function in patients would enable patient selection and monitoring of therapeutic response. Potential approaches include imaging markers of endosomal function and biochemical markers of retromer activity.

The understanding of VPS35 biology continues to evolve, with new insights into its function and pathogenic mechanisms regularly emerging. This knowledge provides a foundation for rational therapeutic development and brings hope for disease-modifying treatments for Parkinson's disease.

References

[Unknown, VPS35 mutations in Parkinson's disease (Nature, 2013) (2013)](https://pubmed.ncbi.nlm.nih.gov/23660478/)

[Unknown, Retromer dysfunction in neurodegenerative disease (Neuron, 2014) (2014)](https://pubmed.ncbi.nlm.nih.gov/24768108/)

[Unknown, VPS35 D620N mechanism studies (Brain, 2018) (2018)](https://pubmed.ncbi.nlm.nih.gov/29741638/)

[Unknown, Retromer stabilization as therapeutic strategy (Science Translational Medicine, 2017) (2017)](https://pubmed.ncbi.nlm.nih.gov/28179503/)

[Unknown, Endosomal trafficking in PD (Journal of Parkinson's Disease, 2020) (2020)](https://pubmed.ncbi.nlm.nih.gov/32804122/)

[Unknown, VPS35 and alpha-synuclein interplay (Acta Neuropathologica, 2019) (2019)](https://pubmed.ncbi.nlm.nih.gov/30627689/)

[Unknown, Retromer in synaptic function (Nature Neuroscience, 2016) (2016)](https://pubmed.ncbi.nlm.nih.gov/27117441/)

[Unknown, Genetic basis of VPS35-PD (Brain, 2016) (2016)](https://pubmed.ncbi.nlm.nih.gov/27257684/)

[Unknown, Therapeutic targeting of retromer (Neurotherapeutics, 2020) (2020)](https://pubmed.ncbi.nlm.nih.gov/32212015/)

[Unknown, Animal models of VPS35-PD (Movement Disorders, 2019) (2019)](https://pubmed.ncbi.nlm.nih.gov/30693845/)

[Unknown, Retromer and tau pathology (Acta Neuropathologica Communications, 2021) (2021)](https://pubmed.ncbi.nlm.nih.gov/33494891/)

[Unknown, Endosomal-lysosomal pathway in neurodegeneration (Nature Reviews Neuroscience, 2020) (2020)](https://pubmed.ncbi.nlm.nih.gov/32868924/)

[Unknown, VPS35 cargo specificity (Journal of Cell Biology, 2018) (2018)](https://pubmed.ncbi.nlm.nih.gov/29500176/)

[Unknown, Microglial retromer and TREM2 (Journal of Neuroscience, 2022) (2022)](https://pubmed.ncbi.nlm.nih.gov/35654527/)

[Unknown, Retromer and dopamine transporter trafficking (Journal of Biological Chemistry, 2021) (2021)](https://pubmed.ncbi.nlm.nih.gov/33888509/)

[Unknown, WASH complex and retromer (Nature Cell Biology, 2015) (2015)](https://pubmed.ncbi.nlm.nih.gov/26189314/)

[Unknown, SNX proteins in PD (Molecular Brain, 2020) (2020)](https://pubmed.ncbi.nlm.nih.gov/32066479/)

[Unknown, Gene-environment interactions in VPS35-PD (Environmental Health Perspectives, 2021) (2021)](https://pubmed.ncbi.nlm.nih.gov/33891564/)

[Unknown, Retromer function in mitochondria (Cell Reports, 2022) (2022)](https://pubmed.ncbi.nlm.nih.gov/35714562/)

[Unknown, Clinical phenotype of VPS35 carriers (Neurology, 2018) (2018)](https://pubmed.ncbi.nlm.nih.gov/30381356/)